The involvement of multiple protease-antiprotease systems and gut origin sepsis in zymosan-associated endothelial barrier injury and multiple organ dysfunction in rats.
Multiple organ dysfunction syndrome is a dominant cause of mortality in the intensive care unit. Experimentally, a condition similar to the multiple organ dysfunction syndrome can be induced by the intraperitoneal injection of sterile zymosan. In the present study we investigate potential alterations in multiple organ functions, endothelial permeability, and antiproteinases after intraperitoneal injection of zymosan at various doses. Zymosan-induced generalized inflammation lead to endothelial barrier injury in multiple organs/tissues, a decrease in systemic arterial pressure, impaired organ function and gut defence function, and consumption of protease inhibitors, particularly the consumption of alpha2 antiplasmin. Endothelial barrier injury appears to present a dose- and organ-dependent pattern in multiple organs/tissues, and the increase in endothelial barrier permeability occurred prior to organ dysfunction. Zymosan induced the development of multiple organ dysfunction syndrome, probably initiating multiple protease-antiprotease systems, particularly the fibrinolytic system, leading to endothelial barrier injury, tissue edema, parenchymal cell damage, and eventual organ dysfunction, potentially augmented by a secondary bacterial infection.
Deng
X
X
Department of Surgery, Lund University Hospital, Sweden.
Wang
X
X
Lasson
A
A
Sun
T Z
TZ
Soltesz
V
V
Andersson
R
R
D000818:Animals; D018988:Bacterial Translocation; D001826:Body Fluids / Q000502:physiology; D004305:Dose-Response Relationship, Drug; D010450:Endopeptidases / Q000502:physiology*; D004727:Endothelium / Q000473:pathology* / Q000502:physiology; D007274:Injections, Intraperitoneal; D008297:Male; D009102:Multiple Organ Failure / Q000139:chemically induced / Q000473:pathology* / Q000503:physiopathology*; D010539:Permeability; D011480:Protease Inhibitors / Q000378:metabolism; D011897:Random Allocation; D051381:Rats; D017207:Rats, Sprague-Dawley; D015054:Zymosan / Q000008:administration & dosage
D011480:Protease Inhibitors; D015054:Zymosan; D010450:Endopeptidases